HomeCompareREPH vs SPHD

REPH vs SPHD: Dividend Comparison 2026

REPH yields 95.69% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 REPH wins by $3.24M in total portfolio value
10 years
REPH
REPH
● Live price
95.69%
Share price
$2.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.26M
Annual income
$1,067,397.24
Full REPH calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — REPH vs SPHD

📍 REPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodREPHSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, REPH + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
REPH pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

REPH
Annual income on $10K today (after 15% tax)
$8,133.97/yr
After 10yr DRIP, annual income (after tax)
$907,287.65/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, REPH beats the other by $906,802.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of REPH + SPHD for your $10,000?

REPH: 50%SPHD: 50%
100% SPHD50/50100% REPH
Portfolio after 10yr
$1.64M
Annual income
$533,984.28/yr
Blended yield
32.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on REPH right now

REPH
Analyst Ratings
7
Buy
2
Hold
Consensus: Buy
Altman Z
-1.1
Piotroski
2/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

REPH buys
0
SPHD buys
0
No recent congressional trades found for REPH or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricREPHSPHD
Forward yield95.69%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$3.26M$26.5K
Annual income after 10y$1,067,397.24$571.32
Total dividends collected$2.90M$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: REPH vs SPHD ($10,000, DRIP)

YearREPH PortfolioREPH Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$20,269$9,569.38$11,133$432.85+$9.1KREPH
2$39,816$18,127.60$12,363$450.36+$27.5KREPH
3$75,882$33,279.13$13,695$467.39+$62.2KREPH
4$140,469$59,275.00$15,138$483.90+$125.3KREPH
5$252,850$102,548.32$16,697$499.88+$236.2KREPH
6$443,065$172,515.34$18,382$515.31+$424.7KREPH
7$756,599$282,519.41$20,198$530.17+$736.4KREPH
8$1,260,443$450,881.99$22,157$544.46+$1.24MREPH
9$2,050,673$701,999.14$24,266$558.18+$2.03MREPH
10$3,261,617$1,067,397.24$26,536$571.32+$3.24MREPH

REPH vs SPHD: Complete Analysis 2026

REPHStock

Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.

Full REPH Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this REPH vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

REPH vs SCHDREPH vs JEPIREPH vs OREPH vs KOREPH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.